NCT04114396

Poor Response to Monoclonal Therapy in Asthma

Investigating Poor Response to Monoclonal Therapy in Asthma

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: University of Nottingham · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

Asthma affects 8% of the entire population. 4-5% of asthma sufferers have severe asthma, characterised by recurrent exacerbations (worsening of symptoms leading to the person having a bout of corticosteroids and/or antibiotics), significant symptoms and lack of response to the most widely used therapy, corticosteroids. There is now new types of treatments (antibody drugs) which are licensed to manage severe asthma such as Anti-IL5. There is evidence Anti-IL5 and other similar antibody drugs are effective at reducing asthma exacerbations and reduce the need for oral corticosteroids for those that have severe asthma. However, some patients respond poorly to Anti-IL5 and the investigators would like to find out why this happens. It is hoped that the investigators can identify the mechanism of poor treatment response to Anti-IL5. It is also hoped that the investigators can understand why symptoms worsen to the point of requiring antibiotics and/or steroids (also known as an exacerbation) for those prescribed Anti-IL5.

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	Anti-IL5 Antibody	Asthma group: Anti-IL5 treatment Control group: No biologic.
PROCEDURE	Bronchoscopy	Optional for both arms

Timeline

• Start date: 2018-12-31
• Primary completion: 2021-06-30
• Completion: 2021-07-31
• First posted: 2019-10-03
• Last updated: 2020-11-03

Locations

1 site across 1 country: United Kingdom